Literature DB >> 28874384

Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.

Nisha A Gilotra1, Aditya Bhonsale2, Cynthia A James2, Anneline S J Te Riele2, Brittney Murray2, Crystal Tichnell2, Abhishek Sawant2, Chin Siang Ong2, Daniel P Judge2, Stuart D Russell2, Hugh Calkins2, Ryan J Tedford2.   

Abstract

BACKGROUND: Heart failure (HF) prevalence in arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) varies depending on study cohort and is not well characterized. This study sought to determine prevalence and predictors of HF in ARVC/D. METHODS AND
RESULTS: Clinical HF, defined as at least 1 HF sign or symptom, was retrospectively adjudicated for 289 patients meeting ARVC/D Task Force Criteria. HF was present in 142 patients (49%): 113 had isolated RV involvement and 29 had evidence of LV dysfunction. Average age of HF onset was 40±14 years. Most commonly reported symptoms were exertional dyspnea (78%) and fatigue (73%). Only 40% (n=57/142) had signs of volume overload. Left-sided HF signs were rare. Patients with clinical HF before ARVC/D diagnosis (n=31) were older (P=0.005) and met fewer Task Force Criteria (P=0.013) than those who developed HF after ARVC/D presentation. Female sex (odds ratio, 2.2; 95% confidence interval, 1.21-4.01; P=0.01) and lateral precordial T-wave inversions (odds ratio, 9.87; 95% confidence interval, 1.07-91.1; P=0.043) were associated with increased odds of HF. Additionally, patients with symptomatic LV dysfunction had higher odds of lateral precordial T-wave inversions (odds ratio, 18.4; 95% confidence interval, 2.92-116.18; P=0.002). Patients with HF were more likely to undergo heart transplantation (15/142 versus 1/147; P<0.001) or die during study follow-up period (7 versus 0; P=0.007).
CONCLUSIONS: HF symptoms, especially exertional dyspnea, are common in ARVC/D; yet, classic left-sided signs are typically absent and less than half have evidence of volume overload. Given the unique predominately right-sided phenotype, a large portion of patients with HF may be under-recognized.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  arrhythmias, cardiac; cardiomyopathies; dyspnea; fatigue; heart failure

Mesh:

Year:  2017        PMID: 28874384     DOI: 10.1161/CIRCHEARTFAILURE.116.003819

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  21 in total

Review 1.  Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report.

Authors:  Perry M Elliott; Aris Anastasakis; Angeliki Asimaki; Cristina Basso; Barbara Bauce; Matthew A Brooke; Hugh Calkins; Domenico Corrado; Firat Duru; Kathleen J Green; Daniel P Judge; David Kelsell; Pier D Lambiase; William J McKenna; Kalliopi Pilichou; Alexandros Protonotarios; Jeffrey E Saffitz; Petros Syrris; Hari Tandri; Anneline Te Riele; Gaetano Thiene; Adalena Tsatsopoulou; J Peter van Tintelen
Journal:  Eur J Heart Fail       Date:  2019-06-18       Impact factor: 15.534

2.  Clinical Classification of Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Yulia Lutokhina; Olga Blagova; Alexander Nedostup; Svetlana Alexandrova; Anna Shestak; Elena Zaklyazminskaya
Journal:  Pulse (Basel)       Date:  2020-02-11

3.  Clinical and genetic features of arrhythmogenic cardiomyopathy: diagnosis, management and the heart failure perspective.

Authors:  Matteo Castrichini; Ramone Eldemire; Daniel W Groves; Matthew Rg Taylor; Shelley Miyamoto; Luisa Mestroni
Journal:  Prog Pediatr Cardiol       Date:  2021-11-02

4.  Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis.

Authors:  Robyn J Hylind; Alexandre C Pereira; Daniel Quiat; Stephanie F Chandler; Thomas M Roston; William T Pu; Vassilios J Bezzerides; Jonathan G Seidman; Christine E Seidman; Dominic J Abrams
Journal:  Circ Genom Precis Med       Date:  2022-05-10

5.  Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient.

Authors:  Weijia Wang; Cynthia A James; Hugh Calkins
Journal:  Europace       Date:  2019-01-01       Impact factor: 5.214

Review 6.  Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An Updated Review of Diagnosis and Management.

Authors:  Yasar Sattar; Hafez Mohammad Abdullah; Elham Neisani Samani; Madhura Myla; Waqas Ullah
Journal:  Cureus       Date:  2019-08-13

7.  Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.

Authors:  Paul J Scheel; Roberta Florido; Steven Hsu; Brittney Murray; Crystal Tichnell; Cynthia A James; Julia Agafonova; Harikrishna Tandri; Daniel P Judge; Stuart D Russell; Ryan J Tedford; Hugh Calkins; Nisha A Gilotra
Journal:  J Am Heart Assoc       Date:  2020-02-03       Impact factor: 5.501

8.  Plasma testosterone and arrhythmic events in male patients with arrhythmogenic right ventricular cardiomyopathy.

Authors:  Jie Ren; Liang Chen; Ningning Zhang; Xiao Chen; Qian Zhao; Kai Chen; Xiangjie Li; Frank Ruschitzka; Firat Duru; Jiangping Song
Journal:  ESC Heart Fail       Date:  2020-05-29

9.  Right Ventricular Strain Predicts Structural Disease Progression in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Nitin Malik; Sithu Win; Cynthia A James; Shelby Kutty; Monica Mukherjee; Nisha A Gilotra; Crystal Tichnell; Brittney Murray; Julia Agafonova; Harikrishna Tandri; Hugh Calkins; Allison G Hays
Journal:  J Am Heart Assoc       Date:  2020-04-03       Impact factor: 5.501

10.  High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy.

Authors:  Monica Chivulescu; Øyvind H Lie; Bogdan A Popescu; Helge Skulstad; Thor Edvardsen; Ruxandra O Jurcut; Kristina H Haugaa
Journal:  Eur Heart J       Date:  2020-04-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.